All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type Gender, female Gender, male PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - (neo)adjuvant (NA), anti-PD-(L)1 vs. Ipilimumab (10 mg/kg), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 238, 2017 0.87 [0.66; 1.14]
0.87 [0.66 ; 1.14 ] CheckMate 238, 2017 1 0% 906 NA not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
0.73 [0.56 ; 0.96 ] CheckMate 238, 2017 1 0% 735 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
0.71 [0.59 ; 0.85 ] CheckMate 238, 2017 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
0.65 [0.51 ; 0.83 ] CheckMate 238, 2017 1 0% 906 NA not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
0.49 [0.20 ; 1.23 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
0.28 [0.21 ; 0.37 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
0.15 [0.10 ; 0.21 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
0.11 [0.07 ; 0.18 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE (any grade)detailed results CheckMate 238, 2017 0.25 [0.15; 0.43]
0.25 [0.15 ; 0.43 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.20 [0.14; 0.27]
0.20 [0.14 ; 0.27 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
0.25 [0.01 ; 5.55 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 238, 2017 0.12 [0.08; 0.17]
0.12 [0.08 ; 0.17 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.09 [0.05; 0.15]
0.09 [0.05 ; 0.15 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.02; 14.96]
0.50 [0.02 ; 14.96 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
0.50 [0.09 ; 2.74 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
0.50 [0.05 ; 5.53 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.03; 2.24]
0.25 [0.03 ; 2.24 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.15 [0.07; 0.34]
0.15 [0.07 ; 0.34 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
0.50 [0.09 ; 2.74 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
0.10 [0.05 ; 0.20 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.14 [0.02; 1.15]
0.14 [0.02 ; 1.15 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
0.15 [0.07 ; 0.32 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 1.00 [0.06; 16.07]
1.00 [0.06 ; 16.07 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.04; 0.81]
0.18 [0.04 ; 0.81 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
0.50 [0.05 ; 5.53 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.02; 0.44]
0.10 [0.02 ; 0.44 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.07; 0.48]
0.18 [0.07 ; 0.48 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.05 [0.00; 0.95]
0.05 [0.00 ; 0.95 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.01; 1.82]
0.10 [0.01 ; 1.82 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
0.25 [0.01 ; 5.55 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.35 [0.13; 0.98]
0.35 [0.13 ; 0.98 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
0.18 [0.07 ; 0.46 ] CheckMate 238, 2017 1 0% 905 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-18 13:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 284,70,235
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
